BofA Raises Biogen Price Target to $200, Focuses on Core Business Performance

Bank of America (BofA) analysts have raised their price target for Biogen's stock to $200. The revision is based on the company's performance in its core business. Analysts updated the target price after assessing Biogen's current operational strength and market position. The new price target reflects the growth potential in the company's main business areas. BofA anticipates that Biogen's neurology portfolio and R&D efforts could create long-term value. However, analysts noted that this assessment is focused on the core business and limits the impact of other factors. Biogen shares saw a slight uptick in pre-market trading following the news. The company's stock performance has recently been closely tied to the approval process and sales expectations for its Alzheimer's drug Leqembi. BofA's price target revision may boost investor confidence in the core business. This is not investment advice.

📊 BIIB — Piyasa Yorumu

▲ up · 65%

BofA's target price increase can be considered a positive catalyst for the stock. Technical indicators also support this view; the RSI at 58.8 is in neutral territory but trending upward, while the MACD is above the signal line and positive. The price is trading above the 20- and 50-day moving averages, indicating strong short-term momentum. However, following a 3.4% rise in the last 24 hours, optimism should be tempered as short-term profit-taking may occur. Overall, the stock is expected to progress toward the $200 target.

RSI 14

58.8

MACD

2.24

24h Δ

3.43%

📊 AMGN — Piyasa Yorumu

■ neutral · 60%

The news headline is related to Biogen and does not directly affect AMGN, but it could create a positive sentiment in the sector. Technical indicators point to a short-term uptrend in AMGN: RSI at 63 is in neutral territory, MACD is above the signal line, and the price is above both the 20-day and 50-day moving averages. There has been a 1.1% increase in the last 24 hours. However, caution is warranted as the news is not directly targeting AMGN and the RSI is approaching overbought territory. Therefore, short-term direction remains uncertain.

RSI 14

63.5

MACD

0.11

24h Δ

1.13%

Canlı Grafikler